Biogen To Pay $900M To Settle Qui Tam Suit Alleging Kickbacks Involving 3 MS Drugs

Mealey's (July 21, 2022, 8:12 AM EDT) -- BOSTON — Drug manufacturer Biogen Inc. has agreed in principle to pay $900 million to settle a whistleblower’s lawsuit that it paid kickbacks to health care professionals to prescribe the company’s...
To view the full article, register now.